Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 4/20 | 0.60 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 11/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102985 | 0.82 | PLAT (0.58) | PLATXDHPIM1PIM2FLT3 | |
| SCHEMBL103383 | 0.78 | PLAT (0.56) | PLATPIM1PIM2 | |
| SCHEMBL17738206 | 0.75 | PLAT (1.00) | PLAT | |
| Hydrochloric Acid SCHEMBL19611560 | 0.75 | PLAT (0.98) | PLAT | |
| SCHEMBL102845 | 0.73 | PIM1 (0.60) | PIM1PIM2FLT3KCNH2 | |
| SCHEMBL14653595 | 0.73 | PIM1 (0.63) | XDHPIM1PIM2FLT3KCNH2 | |
| SCHEMBL22421461 | 0.72 | PIM1 (0.54) | PIM1PIM2FLT3KCNH2NPY5R | |
| SCHEMBL19986934 | 0.68 | PIM1 (0.76) | PIM1PIM2FLT3KCNH2 | |
| SCHEMBL4330227 | 0.68 | PIM1 (0.65) | PIM1PIM2FLT3KCNH2 | |
| SCHEMBL4337283 | 0.67 | PIM1 (0.67) | PIM1PIM2FLT3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | disclosed |
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3409278-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3409278-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200102313-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2020-04-02 | — | — | US | disclosed |
| US-10392392-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190071446-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2019-03-07 | — | — | US | disclosed |
| US-9416132-B2 | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2734205-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Tolero Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013013188-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013013188-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM2, PIM1, PIM3 | PLAT 1416/4885XDH 3769/4885PIM1 2/4885 |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PLAT 1251/4885XDH 1616/4885PIM1 1/4885 |
| US-20190071446-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PLAT 1809/4885XDH 2625/4885PIM1 1/4885 |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PLAT 1809/4885XDH 2625/4885PIM1 1/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PLAT 1809/4885XDH 2625/4885PIM1 1/4885 |
| US-20200102313-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PLAT 1809/4885XDH 2625/4885PIM1 1/4885 |
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PLAT 1555/4885XDH 2409/4885PIM1 1/4885 |
| US-10392392-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM1, PIM2, PIM3 | PLAT 1560/4885XDH 2123/4885PIM1 1/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PLAT 1809/4885XDH 2625/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.